REDWOOD CITY, Calif. , Aug. 6, 2024 /PRNewswire/ -- Galvanize Therapeutics, Inc.
, a leader in developing pulsed electric field therapies for chronic bronchitis and solid tumors, has completed enrollment in the AFFINITY study evaluating Aliya PEF ablation in patients with stage IV non-small cell lung cancer (NSCLC) or metastasis to the lung who are not surgical candidates. The 30-patient study is examining the safety of adding Aliya PEF, delivered either bronchoscopically or percutaneously, to standard of care therapies for these advanced disease patients and further assessing immune stimulation and treatment effect. "Completing enrollment in AFFINITY is a significant milestone towards our goal of providing patients with solid tumors a biology-based therapy that extends beyond focal ablation," said Jonathan Waldstreicher , M.
D., Founder and CEO of Galvanize Therapeutics. "We look forward to reporting the results next year.
" Aliya delivers high voltage, short duration electrical energy locally to alter the transmembrane potential of cells, which results in loss of homeostasis, inducing non-thermal programmed cell death without denaturing cellular proteins and the extracellular matrix. In addition to focal ablation, preclinical and prior clinical feasibility studies suggest this process may release antigens from the dying tumor cells that may stimulate an immune response for a potential systemic effect beyond focal ablation. Aliya can be delivered percutaneously or endoscopicall.